Scientists at Scripps Research have developed a urine diagnostic to detect the parasitic worms that cause river blindness, also called onchocerciasis, a tropical disease that afflicts 18 to 120 million people worldwide.
Described in the journal ACS Infectious Diseases, the new, non-invasive test may provide an inexpensive method of determining in real time whether a person has an infection, which would give public health officials and doctors critical information for tracking outbreaks and treating current infections.
“River blindness affects individuals both in Africa and Latin America, and because many of these endemic regions are difficult to access, what is needed in the field is an inexpensive point-of-care means to monitor the disease,” says Kim Janda, PhD, the Ely R. Callaway Jr. Professor of Chemistry and member of the Skaggs Institute for Chemical Biology at Scripps Research.
River blindness is a filarial disease, like elephantiasis, and occurs when the parasitic worm Onchocerca volvulus takes up residence in the skin. Adult worms pump out babies (microfilaria) at an alarming rate, which are ultimately re-spread by blackfly bites. The microfilariae can migrate to the eye and die, releasing toxins and causing inflammation. People with the disease will slowly go blind without medical intervention.
Janda says onchocerciasis monitoring and evaluation are especially necessary steps for people leading elimination efforts. To know if these efforts are working, doctors need to be able to show when disease transmission has been interrupted. The current gold standard for detecting the parasitic worms is a “skin snip” biopsy. However, snips are generally insensitive indicators of infection, and the sensitivity of the skin snip decreases as the density of microfilaria in the skin decreases. Other tests cannot distinguish between past and current infections.
Currently, onchocerciasis elimination programs rely primarily on mass drug administration of the therapy Ivermectin to suppress and eventually eliminate transmission of Onchocerca volvulus. Yet, without a means to evaluate if an infection is ongoing, it’s hard to assess if prevention efforts are working—and if it’s safe for people to stop taking medication.
The new lateral flow assay took over 10 years to develop, but it is now ready for manufacturing and testing in the field. The key to the assay’s success was in the making of designer antibodies to detect a unique biomarker that only shows up when a human host has metabolized a worm neurotransmitter called tyramine. Humans then secrete this biomarker in urine.
A negative on the “dipstick” test shows a colored line in the test. Got the parasite? The test would show no lines.
Unlike the skin snip biopsy, Janda says this non-invasive test is the first to use a metabolite produced by adult worms. Moreover, the dipstick’s inexpensive design, coupled with smartphone apps, would offer automatic image processing, which ultimately could translate to address critical gaps in the surveillance and treatment of river blindness.
Receive an email update when we add a new RIVER BLINDNESS article.
The Latest on: River blindness
via Google News
The Latest on: River blindness
- Researchers Analyze Genomes of 81 Parasitic Worm Species on November 5, 2018 at 4:07 pm
The results, published today (November 5) in Nature Genetics, could lead to treatments for illnesses caused by the parasites, such as river blindness, schistosomiasis, and hookworm disease. “Little is ... […]
- Alcami Helps Medicines Development for Global Health Secure FDA Approval of Moxidectin for River Blindness on October 25, 2018 at 11:06 am
"Our colleagues at Medicines Development for Global Health have reached a significant milestone," said Alcami Chief Commercial Officer, Syed T. Husain. "We are very pleased to have helped MDGH navigat... […]
- Alcami Helps Medicines Development for Global Health Secure FDA Approval of Moxidectin for River Blindness on October 24, 2018 at 5:00 pm
DURHAM, N.C., Oct. 25, 2018 /PRNewswire/ -- Alcami Corporation, a leading provider of fully-integrated custom end-to-end solutions for the pharmaceutical and biotechnology industries, announced today ... […]
- After an epic research journey, an inexpensive, practical test for river blindness on August 28, 2018 at 6:40 am
A practical test for river blindness, a parasitic tropical disease that affects more than 18 million people, and puts 120 million at risk, has been developed by a Scripps Research scientist. Unlike ex... […]
- New urine dipstick test detects cause of disease that blinds millions on August 28, 2018 at 6:05 am
Scientists at Scripps Research have developed a urine diagnostic to detect the parasitic worms that cause river blindness, also called onchocerciasis, a tropical disease that afflicts 18 to 120 millio... […]
- Ugandan Doctor Co-Finds New River Blindness Drug on June 18, 2018 at 12:50 am
Kampala — Ugandan doctor Amos Nyathirombo is celebrating a scientific milestone after a six-year World Health Organisation-led research he co-participated in found a more effective River Blindness dru... […]
- Ugandan doctor co-finds new River blindness drug on June 17, 2018 at 11:21 am
Born in Zombo District, Dr Nyathirombo, 52, is an eye specialist and lecturer in the Department of Ophthalmology at Gulu University. He previously lectured at Makerere University after working at Arua ... […]
- Guinea worm, river blindness and elephantiasis are among the world's neglected tropical diseases. A battle is on to wipe them out on December 14, 2017 at 4:05 am
One infection known as dracunculiasis can cause people to suffer a burning blister that bursts as a parasite called the Guinea worm breaks through the skin. Another one, elephantiasis, causes grotesqu... […]
via Bing News